ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus
Open Access
- 7 January 2002
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (1) , 5-11
- https://doi.org/10.1038/sj.bjc.6600006
Abstract
Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically modified viruses resemble the basis for new promising cancer therapeutics. The main advantages of employing replication-competent viruses are achievement of tumour selective killing and amplification of their oncolytic potential within the tumour mass. In this review, we describe the development of ONYX-015, one of the first and most advanced replication-competent viruses for cancer therapy. We discuss the molecular biology of this therapeutic approach and the interesting results obtained with this virus in clinical trials.Keywords
This publication has 59 references indexed in Scilit:
- Wild-Type Adenovirus Decreases Tumor Xenograft Growth, but Despite Viral Persistence Complete Tumor Responses Are Rarely Achieved—Deletion of the Viral E1b-19-kD Gene Increases the Viral Oncolytic EffectHuman Gene Therapy, 2001
- Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosisGene Therapy, 2001
- Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53The EMBO Journal, 1999
- VIRAL TRANSACTIVATING PROTEINSAnnual Review of Genetics, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Cancer Cell CyclesScience, 1996
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- The multistep nature of cancerTrends in Genetics, 1993
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- The p53 tumour suppressor geneNature, 1991